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Abstract
Background: The health benefits of polyunsaturated fatty acids (PUFAs), particularly those of the n-3 series are well 
documented. The mechanisms by which these effects are mediated are not fully clarified.
Methods: We used microarrays to assess the effects on gene expression in HT29 colon adenocarcinoma cells of 
exposure to the n-3 fatty acid eicosapentaenoic acid (EPA). HT29 cells were cultured with EPA (150 μM) for up to 24 hr 
prior to harvesting and isolation of RNA. Microarray results were analyzed within the statistical package 'R', and GeneGo 
MetaCore was used to identify key pathways of altered gene expression.
Results: EphB4, Vav2 and EphA1 gene expression were identified as significantly altered by EPA treatment. Statistically 
significant changes in gene expression after HT29 exposure to EPA were confirmed in a second experiment by real-
time RT-PCR (TaqMan), This experiment also compared the effects of exposure to EPA to arachadonic acid (AA, n-6). 
Corresponding changes in protein expression were also assessed by Western blotting.
Conclusions: Eph receptor mediated signaling is an entirely novel signaling pathway through which EPA may promote 
a wide range of health benefits, in particular in relation to reduction of colorectal cancer progression.
Background
Polyunsaturated fatty acids (PUFAs), and in particular
those of the n-3 series found in fish oil, are well recog-
nized to have a wide range of health benefits [1]. However
the mechanisms by which they mediate their beneficial
physiological effects at the cell signaling level are still
poorly understood. The importance of PUFAs in modu-
lating cell function via control of gene transcription has
been recognized for over a decade [2]. The potential com-
plexity of the various signaling mechanisms involved
when cells are exposed to PUFAs is discussed in a review
by Tang et al. [3]. For example they, and the wide range of
signaling molecules derived from them, act as ligands to
PPARs. They may also change the fluidity of cell mem-
branes and thus influence receptor activity, and they can
also modify the redox state, which in turn will influence a
wide range of signaling pathways. It is entirely feasible to
raise plasma and tissue fatty acids to levels which have
been shown to be biologically active in vitro by taking fish
oil capsules [4], and probably by consuming oil-rich fish
[5,6]. For example, in volunteers consuming 3 g fish oil
per day for 18 weeks, plasma concentrations of the two
long chain n-3 fatty acids eicosapentaenoic acid (EPA;
C20:5) and docosahexaenoic acid (DHA; C22:6) reached
concentrations in excess of 300 μM [4]. Similarly Gee et
al. have shown that consuming fish oil capsules leads to a
significant increase in EPA concentration in colon biopsy
tissue [7].
The potential importance of dietary n-3 fatty acids in
relation to colorectal cancer prevention has become
increasingly well recognized over the last decade. Epide-
miological studies have shown that high fish consump-
tion is associated with a reduced incidence of colorectal
cancer [8] and in vitro studies have provided evidence of
potential mechanisms. Animal studies, using a chemical
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model of colorectal cancer, have shown that dietary fish
oil both reduces cell proliferation and induces apoptosis
[9,10]; changes which are associated with a reduction in
the formation of aberrant crypt foci. In humans, con-
sumption of n-3 fatty acids has been shown to reduce
crypt cell proliferation rate in the colon and rectum of
patients at risk of developing colorectal cancer [11] and
this finding is associated with a reduction in the number
of polyps [12]. Additionally these highly unsaturated fatty
acids have been shown to induce apoptosis in cultured
colorectal carcinoma cells at concentrations within the
range found in plasma. While both EPA and DHA have
been shown to have anticarcinogenic effects, previous
studies in our group have specifically shown effects of
EPA on tumor suppression [13]. Although a number of
potential mechanisms by which fish oil derived fatty acids
may protect against colorectal cancer have been sug-
gested including modifying gene expression either
through response to oxidative stress or via PPAR signal-
ing [14-17], the molecular mechanism by which a high-
fish diet, mediates these effects needs clarification. The
aim of this study was to identify novel pathways by which
the n-3 PUFA, EPA, may modify tumor progression.
W e ha ve used micr oarra y analysis t o make an initial
assessment of changes in expression of genes in HT29
colon adenocarcinoma cells over a 24 hr period following
exposure to EPA. This timescale was chosen as a result of
an initial screening study which showed that EPA treat-
ment was linked to modified redox potential within the
cell, as measured by the ratio of oxidized to reduced glu-
tathione, such that this ratio was doubled from 2-4 hr
post exposure, before returning to baseline. Meanwhile
total glutathione levels showed a steady decline to about
50% of the initial value over 24 hr (unpublished data). In
the present study, pathway analysis was carried out to
assess which pathways were modulated by EPA treat-
ment. This identified genes involved in ephrin (Eph)
receptor signaling as of key importance.
In order to assess the specificity of the effects of differ-
ent PUFA classes on this signaling pathway we conducted
a second experiment, using real-time RT-PCR to investi-
gate changes over time, in those genes identified by
microarray. In this experiment HT29 cells were exposed
to either EPA or arachadonic acid (AA), relative to
changes in control cells not exposed to PUFA. Exposure
to AA was used to compare the effects of a highly unsatu-
rated n-3 PUFA (EPA, C20: 5) with a similarly unsatu-
rated n-6 PUFA (AA, C20:4). If the effects of PUFA were
associated purely with changes in redox potential it might
be expected that both fatty acids would show similar
effects, whereas if they act as ligands for nuclear recep-
tors they may be expected to cause different effects [18].
Finally the changes identified at the gene level have then
been assessed at the protein level by western blotting.
Methods
Cell culture
The human colonic epithelial cells were obtained from
European collection of cell cultures (ECACC). The cells
were cultured under standard culture condition in Dul-
becco's modified Eagle's medium (DMEM) (Sigma) sup-
plemented with 10% fetal bovine serum, 2 mM L-
glutamine and 1% penicillin-streptomycin. The cells were
maintained at 37°C and 5% CO2 in a humid environment.
Treatment of cells
Two separate experiments were carried out. The first
experiment focused on identifying novel signaling path-
ways associated with exposure to EPA using microarray
analysis. The second was designed to confirm results
found by array analysis and to compare with the effects of
an n-6 polyunsaturated fatty acid AA. EPA (E-2011) and
AA (A-9673) were purchased from Sigma and diluted in
ethanol to 25 mg/ml. These stocks were stored at -20°C
under nitrogen to prevent oxidation. 75 cm2 flasks were
seeded with 6 × 106 cells in 25 ml medium and left to
adhere for 24 hr. After this time the medium was
removed and replaced with either 25 ml fresh medium
(control) or 25 ml medium containing EPA (EPA treated)
or 25 ml medium containing AA (AA treated) at a final
concentration of 150 μM. The medium contained 0.2%
ethanol which is sufficiently low to disregard solvent
effects. This concentration was chosen as a result of pre-
liminary experiments showing this was the maximum
that did not lead to reduction in cell number, over 24 hr
incubation as shown by neutral red cell viability assay
[19]. Four flasks of control cells and four flasks of EP A
treated cells were harvested with trypsin within 20 min of
the media change (t = 0 hr) and then at 1, 2, 4, 6, 8, and 24
hr for microarray analysis. For real-time RT-PCR analy-
sis, 3 flasks of EPA, AA and untreated cells were har-
vested at all the time points. For protein analysis, 3 flasks
of each treatment (EPA, AA and untreated) were har-
vested immediately and at 2, 6, 8 and 24 hr. Cells were
stored as a dry pellet at -80°C prior to extraction of RNA
or protein. The cells for microarray analysis were grown
and treated on different dates to those grown and treated
for real-time RT-PCR and protein analysis.
RNA extraction
Total RNA was extracted using Qiagen RNeasy mini and
midi kits as appropriate. The eluted total RNA was stored
at -80°C. The concentration and quality of the RNA was
determined by Agilent lab-on-a-chip RNA 6000 nano
chips. Accuracy of concentration was checked with a sub-
set of samples on a spectrophotometer. A large pool of
HT29 RNA was also extracted for use as a reference RNA
sample for the microarray analysis. For real-time RT-PCR
analysis, the integrity of all RNA samples was confirmedDoleman et al. Nutrition & Metabolism 2010, 7:56
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using the Agilent lab-on-a-chip bioanalyser and the RNA
concentrations were determined using the nano drop
ND-1000 spectrophotometer.
Experiment 1: Microarray analysis
Cy3 (test sample) and Cy5 (reference sample) labeled
cDNA extracts were prepared by reverse transcription of
the RNA samples obtained from the HT29 cells in the
presence of amino-allyl dUTP to enable subsequent cou-
pling with the Cy dyes (GE Healthcare Life Sciences)
using a well established protocol [20]. The labeled cDNA
samples were hybridized to in-house printed oligonucle-
otide arrays as described previously [21]. The array con-
sists of 13,971 gene-specific oligonucleotides, 29 negative
controls and 1 positive control (an equimolar mixture of
the 13,971 gene-specific oligonucleotides). The arrays
were scanned using an Agilent G2565BA microarray
scanner system (Agilent Technologies). The raw signal
intensities for the features on the microarrays were
extracted using Axon GenePix 4.0 software (Axon Instru-
ments). Bad features, identified by visual inspection, were
flagged as such manually. All microarray data has been
deposited into ArrayExpress public repository. Accession
code: E-MEXP-2673.
S u b s e q u e n t  d a t a  a n a l y s e s  w e r e  r e s t r i c t e d  t o  f e a t u r e s
flagged automatically by the software as present. Array
data analysis was performed using R http://www.R-proj-
ect.org and GeneGo MetaCore (GeneGo bioinformatics
software, Inc.).
Raw un-normalized array data were uploaded into the
statistical package 'R', using the Limma package, and bad
flagged spots were omitted. Data were normalized with
Lowess print tip normalization and, as a standard refer-
ence sample was used in the Cy5 channel, normalization
between arrays was performed using the GQuantile
approach. Differences between test and control at specific
time points were determined, taking into account the dif-
ferences at baseline T0. Fold change data was determined
for the data with an adjusted p value of < 0.05 with a Ben-
jamini Hochberg multiple test correction factor.
The ID, unigene number, adjusted p value and fold
change data obtained in R for differences between test
and control at individual time points were uploaded into
MetaCore and a workflow data analysis report per-
formed. This generated lists of significantly altered genes
that showed changes in expression level at more than one
time point. The greatest number of significantly altered
genes common between time points was found for 8 hr
and 24 hr. The resultant list of common genes between 8
hr and 24 hr was used to build networks of associated
pathways and processes. Pathways were sorted for impor-
tance by the G-score. The G-score modifies the Z-score
(the rank according to saturation of genes from the exper-
iment) based on the number of Canonical Pathways used
to build the network. If a network has a high G-score, it is
saturated with expressed genes (from Z-score) and it con-
tains many Canonical Pathways. Sorting the table by this
value essentially enables you to sort the table by two fac-
tors at once.
Experiment 2: Effect of EPA and AA on gene and protein 
expression
In order to determine whether the identified changes in
gene expression were specific to the n-3 fatty acid EPA,
rather than a generic response to the presence of any fatty
acid, cells were treated with either EPA, or an n-6 fatty
acid (AA), or left untreated (controls). RNA and protein
were extracted at a range of time points from 0 to 24 hr
and these samples were analyzed by real-time RT-PCR
and western blotting, respectively. RNA samples from
cells treated with different fatty acids were analyzed for
EphB4, Vav2 and EphA1 expression.
Real-time RT-PCR analysis
RNA samples from EPA, AA and untreated HT29 cells
were prepared and analyzed for integrity and concentra-
tion as detailed previously. 100 μl reverse transcription
reactions were prepared with 2 μg RNA, 2.5 μM polyN
(15mer) primer (Operon) and all other reagents were
provided from Applied Biosystems TaqMan reverse tran-
scription reagent kit (#n8080234). Reactions were per-
formed in a 96 well plate following manufacturers
protocol. cDNA samples were stored at -80°C prior to
use.
Primers and probes were designed using the Universal
Probe Library Assay Design Centre, by Roche Applied
Science. Primers were then purchased from Sigma Geno-
sys and probes from Roche Applied Science. All reactions
were prepared using the Corbett robot and run on
A p p l i ed  B i osys t e m s  AB  O n e  S t e p  P l us  u n d e r  s t a n da r d
conditions with 200 nM each primer, 100 nM probe and
Applied Biosystems TaqMan Gene Expression master
mix (#4369016) in a total reaction volume of 20 μl. All
primer sequences and corresponding probes are shown
in Table 1.
To enable us to compare gene expression changes in
this experiment with those identified by microarray anal-
ysis in the first experiment, the data for EPA treated cells,
normalized using β-actin expression, were then expressed
relative to untreated control cell data at the same time
point for both data sets, before normalizing to the expres-
sion level immediately after media change
Protein sample preparation and western blotting
Protein extracts were prepared from frozen cell pellets of
untreated, EPA treated and AA treated HT29 cells using
RiPa lysis buffer (Santa Cruz SC-24948) as per manufac-
turer's instruction. Samples were stored at -80°C. Pre-
stained protein molecular weight marker was purchasedDoleman et al. Nutrition & Metabolism 2010, 7:56
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Page 4 of 12
from New England Biolabs (P77085). MagicMark western
protein standard (LC5600) was purchased from Invitro-
gen life technologies. Protein concentration of samples
was determined using BCA assay kit (#23227) purchased
from Thermo Scientific and used as per manufacturer's
instructions. NuPage Novex 10% bis-tris gel 1.0 mm 12
well gels, NuPage LDS sample buffer, NuPage transfer
buffer, NuPage MOPS SDS running buffer for bis-tris gels
and NuPage antioxidant were all purchased from Invitro-
gen life technologies. 20 μg protein was incubated with 1
μl 0.5 M DTT and 4 × NuPage buffer at 70°C for 10 min.
Gels were run following standard conditions at 200 V for
50 min and then transferred to PVDF membrane using
the Novex transfer system for 60 min at 30 V.
Mouse monoclonal to Eph receptor B4 (ab70404), rab-
bit monoclonal to Vav2 (ab52640), rabbit polyclonal to
Eph receptor B4 (ab64820) and rabbit polyclonal to beta
actin (ab8227) were all purchased from Abcam. Beta
actin was selected for use as the loading control to allow
direct comparison with the normalized gene expression
data from real-time RT-PCR analysis. After transfer,
membranes were briefly washed in superblock T20 (TBS)
blocking buffer (Thermo Scientific) and blocked for
either 60 min at room temp or overnight at 4°C. Primary
antibodies were incubated overnight at 4°C at appropriate
concentrations. Membranes were washed 4 times in Tris
buffered saline and then incubated with appropriate
horseradish peroxidase (HRP) conjugated secondary
antibody (HRP conjugated anti-mouse antibody (NA931)
and HRP conjugated anti-rabbit antibody (NA934) both
from GE healthcare). Bands were detected with Amer-
sham ECL plus western blotting detection reagents and
visualized using a BioRad Fluor-S Multimager. Blots were
stripped for re-probing with Re-Blot plus (Chemicon
International) following manufacturer's standard proto-
col.
Statistical Analysis
All statistical analysis apart from the array analysis (dis-
cussed above) was conducted using the Minitab Package
(version X1). Gene expression data is expressed as log2
mean values with standard deviations represented on
these plots in proportion to the logged value based on the
standard deviation of the unlogged mean. Protein data is
expressed as mean and standard deviation. Two-way
analysis of variance using the General Linear Model and
Tukey post-hoc tests were carried out on logged gene
expression data and unlogged protein data to examine the
effects of treatment over time. Each time point and each
treatment was treated as an independent variable.
Results
Experiment 1: Microarray analysis
In total 48 arrays were analyzed in R, 335 genes were
identified as significantly altered between EPA treated
and untreated control cells at T = 8 hr and more than 500
genes were identified as significantly altered between
EPA treated and untreated control cells by 24 hr. The
number of significantly altered genes at each time point is
shown in Table 2 and the list of genes identified as signifi-
cantly modified are shown in Additional file 1, Table S1. It
is beneficial to maximize the information that can be
gleaned from array data sets by looking for genes with
similar ontology, or that are involved in the same bio-
chemical pathway [22]. To this end the R analyzed data
was uploaded into GeneGo MetaCore™ for network and
pathway analyses [23] and identification of shared gene
ontologies (GO processes) that were significantly altered
by EPA treatment.
GeneGo MetaCore identified 155 genes that were sig-
nificantly altered at both 8 hr and 24 hr and with these a
list of 30 networks were identified. The highest scoring
network identified by GeneGo MetaCore was for the
Ephrin receptor (p < 7.00 × 10-11) (Table 3). Additional
file 2, Figure S1 shows the simplified Ephrin receptor net-
work created in MetaCore. Pathway analysis revealed sig-
nificantly altered pathways for T = 8 hr and T = 24 hr. The
top ten significantly modified pathways are shown in
Additional file 3, Table S2. The Ephrin pathway was
fourth ranked most significantly altered pathway identi-
fied and from this three key genes EphB4, EphA1 and
V a v 2  w e r e  i d e n t i f i e d  o n  a s  h a v i n g  s i g n i f i c a n t l y  a l t e r e d
Table 1: Primer sequences and corresponding probe numbers for real-time RT-PCR analysis
Gene Forward primer Reverse primer Roche Universal Probe Library probe
EphB4 gcccgtcatgattctcaca gaactgtccgtcgtttagcc 12
EphA1 gcatgaaacgctacatcctg gtgattcccatctgcgtca 67
Vav2 catcaaggtggaggtgcag gtacttggcctcggtctcct 67
β-actin ccaaccgcgagaagatga ccagaggcgtacagggtag 64Doleman et al. Nutrition & Metabolism 2010, 7:56
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gene expression p < 0.05 as a result of EPA treatment
(Table 4 and Additional file 4, Figure S2).
Experiment 2: Effect of EPA and AA on gene and protein 
expression
Increased expression of EphB4 and EphA1 relative to
untreated control cells was seen at both 8 hr and 24 hr
and Vav2 expression was also up-regulated after 24 hr
exposure to EPA as measured by microarray analysis (Fig-
ure 1). The observed changes in expression of Vav2 were
very similar in both the first experiment using microarray
analysis and in the second experiment using real-time
RT-PCR. Similarly, at 8 hr and 24 hr EphB4 expression
was similar in both experiments but not at the time
points immediately following media change. Although
EphA1 showed increased expression in response to EPA
in the first experiment, this was not seen in the second.
The effects of different fatty acids on gene expression
are shown in figure 2. Analysis of the complete data set
for EphB4 using two-way ANOVA showed a significant
effect of treatment (p < 0.001) and time (p < 0.02). The
effect of time in relation to EphB4 expression was only
weakly significant for untreated cells (p = 0.09) but was
significant for EPA (p = 0.005) and AA (p = 0.009). Com-
parison of different treatments at each time point using
ANOVA showed that expression of EphB4 was increased
following EPA treatment compared to AA treated cells (p
= 0.04) at 8 hr post treatment, and weakly significantly
compared to untreated control cells (p < 0.09). This effect
was still apparent at 24 hr although this did not quite
achieve statistical significance compared to controls.
Analysis of data over time for each treatment group
showed that EPA and AA treatment appeared to produce
similar gene expression profiles for EphB4 at time points
up to 6 hr. EPA led to an initial reduction in expression at
4-6 hr followed by increased expression at 8 hr (p = 0.02
comparing t = 4 hr and t = 6 hr with t = 8 hr post EPA
exposure) AA treatment was associated with a drop in
EphB4 expression at t = 4 hr (p = 0.01) relative to t = 8 hr.
Analysis of the complete data set for Vav2 gene expres-
sion using two-way ANOVA showed a significant effect
of time (p < 0.001) and treatment (p = 0.003). Overall the
expression of Vav2 decreased following media change,
suggesting a generalized stress response to this process.
All treatments showed a significant time dependent effect
(untreated p = 0.003, AA treated p < 0.001 and EPA
treated p = 0.003). Comparison of treatments at each
time point showed that at 2 hr AA treated cells had lower
expression levels than EPA treated cells (p = 0.005) and
untreated cells (p < 0.05) but otherwise the profiles were
all very similar.
No significant differences in gene expression were
shown for EphA1 by EPA, AA or untreated cells across
the time course. EphA1 was therefore omitted from fur-
ther investigation by western blotting.
Protein samples from cells treated with EPA, AA or
untreated cells were analyzed by western blotting for
EphB4 and Vav2 expression and normalized to β-actin
(Figure 3). Up to 8 hr no EphB4 protein was detectable.
This is consistent with a very low abundance of the gene
product particularly at the early time points. At 8 hr pro-
tein was detectable but expression in cells treated with
EPA was significantly lower with respect to both
untreated (p = 0.007) and AA treated cells (p = 0.034). By
24 hr there was still a trend for EPA treated cells to show a
slight down-regulation in EphB4 expression as compared
to both AA and untreated cells but this was no longer sig-
nificant. In fact, the up-regulation in expression for all
three treatments between 8 hr and 24 hr was highly sig-
nificant (p < 0.005 in all cases). Thus there is an effect of
'time since media change' or 'length of cell culture' on top
of which we see the down-regulation of EphB4 protein by
EPA.
Vav2 protein expression was significantly up-regulated
after 4 hr irrespective of treatment (p < 0.05). At 8 hr lev-
els of Vav2 protein were significantly elevated by EPA
treatment as compared to untreated control cells (p <
0.05). EPA treatment led to an apparent increase in Vav2
protein levels as compared to AA treatment but this was
not significant. By 24 hr the significant increases in pro-
Table 2: The number of significantly altered genes between 
EPA treatment and untreated cells as identified by 
microarray
Timepoint Number of significantly altered genes
p < 0.05 p < 0.01
T = 0 hrs 3 1
T = 1 hrs 226 48
T = 2 hrs 1 1
T 4 hrs 102 37
T = 6 hrs 34 15
T = 8 hrs 335 38
T = 24 hrs 543 140
The number of genes identified by microarray and analyzed in R, 
including Benjamini and Hochberg multiple test correction, as 
significantly altered between EPA treated and untreated HT29 
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Table 3: The highest G-score networks and corresponding processes identified using MetaCore 
Networks GO Processes‡ Significantly changed genes involved p-value G-score
Ephrin-B receptors,
Ephrin-A receptors,
Connexin 32,
Twinfilin,
FXR1/2
cell projection organization and biogenesis (43.8%; 
1.652e-19)
cell projection morphogenesis (43.8%; 1.723e-19)
cell part morphogenesis (43.8%; 1.723e-19)
cell morphogenesis (45.8%; 1.974e-18)
cellular structure morphogenesis (45.8%; 1.974e-18)
Receptors: Ephrin-B receptors ￿; Ephrin-B receptor 4 ￿; Ephrin-A 
receptors ￿
Regulators: Vav2 ￿
Binding Protein: Twinfillin ￿; Alpha Actin ￿
Channels: Connexin 32￿
Protein: FXR1/2 ￿; VAMP4 ￿
GTPase: CDC42 ￿
7.00e-11 91.44
FXR,
FXR/RXR-α,
GIPC,
SOX3,
Pitpnm (NIR2)
V(D)J recombination (6.8%; 5.712e-06)
response to stimulus (56.8%; 1.109e-05)
B cell homeostatic proliferation (4.5%; 2.286e-05)
organ morphogenesis (25.0%; 2.353e-05)
bile acid metabolic process (6.8%; 4.487e-05)
Transcription Factor: SOX3 ￿; TITF1 ￿￿; FXR ￿
Receptors: Syndecan-1 ￿
Binding Protein: Fetulin-A ￿; Pitpnm (NIR2) ￿￿; GIPC ￿; SYNE2 ￿; 
Actin ￿; RAD23A ￿￿
Channels: Kir3.3 ￿
Transporter: SLC6A6 ￿￿; Glut1 ￿
Protein: COQ4 ￿
Lipid Kinase: P3C2B ￿; PI3K class II ￿
3.08e-23 36.22
SET1A,
Autophagin-1,
ASNS,
ETV6(TEL1),
POP1 (RNase P/MRP subunit)
tRNA catabolic process (7.7%; 2.622e-06)
tRNA 5'-leader removal (7.7%; 7.859e-06)
ncRNA catabolic process (7.7%; 1.570e-05)
autophagy (11.5%; 2.111e-05)
intracellular transport (30.8%; 1.049e-04)
Transcription Factor: ETV6 (Tel1) ￿
Binding Protein: PEX3 ￿;FXR 2￿; Histone H2A ￿
Protease: Autophagin-1￿
Enzyme: GSHB ￿; ASNS ￿; Set1A ￿; POP1 (RNaseP/MRP subunit) ￿
Protein: ES1 ￿
1.66e-20 35.43
NF-kB,
Large 39 S subunit,
MRPL16,
2'-5'-oligoadenylate 
synthetase,
TIEG
response to UV (27.3%; 3.661e-10)
nucleotide-excision repair, DNA damage removal (18.2%; 
3.547e-08)
nucleotide-excision repair, DNA incision (13.6%; 1.320e-
07)
DNA catabolic process, endonucleolytic (13.6%; 1.978e-07)
response to light stimulus (27.3%; 2.314e-07)
Transcription Factor: TIEG ￿
Binding Protein: Fetulin-A ￿; MRPL16 ￿; MRPL37 ￿ XPA ￿; P21 ￿
Enzyme:2'-5' oligoadenylate synthetase ￿
SULT1A1 ￿
Kinase: PRKX ￿
1.45e-17 35.39
‡ (% refers to objects on network belonging to process; p-value showing statistical significance of the GO process on that network)Doleman et al. Nutrition & Metabolism 2010, 7:56
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Page 7 of 12
tein levels induced by EPA treatment had diminished and
there was no difference between treatments.
There was no apparent correlation between gene
expression and protein levels even taking into account the
expected delay between changes in gene expression and
increased or decreased protein levels.
Discussion
Although it is well documented that n-3 PUFAs may have
a range of health benefits including improved cognitive
function [24] and suppression of carcinogenesis [25], the
mechanisms by which these effects are mediated are still
far from clear. However, PUFAs are known to affect gene
transcription by a number of routes that remain imper-
fectly understood [26]. In order to obtain new insight into
potential novel signaling pathways by which PUFAs may
act, we investigated changes in gene expression in Meta-
Core following exposure to EPA using microarray analy-
s i s .  G e n e G o  M e t a C o r e  a n a l y s i s  o f  t h e  d a t a  w a s
performed to identify pathways modulated by EPA treat-
ment to try and clarify mechanisms by which a high fish
diet may exert benefit. The highest scoring network iden-
tified by GeneGo MetaCore was for the Ephrin receptor.
This network is particularly associated with cell morpho-
genesis including factors associated with cytoskeletal
structure, formation of cell contacts and adhesion to the
extracellular matrix; all factors important in both cancer
prevention and cognitive function. Three key genes were
identified by microarray, EphB4, EphA1 and Vav2, on the
associated pathway as having significantly increased gene
expression as a result of EPA treatment. These three
genes were chosen for further gene expression analysis by
real-time RT-PCR and protein analysis by western blot-
ting in order to substantiate the array findings. The Eph
receptor family is one of the largest groups of receptor
protein kinases [27]. The Ephs (receptors) and their
ligands (ephrins) can be divided into two subclasses, A
and B, on the basis of sequence homology, structure and
binding affinity [28]. Altered expression of Eph receptors
and their ephrin ligands has been reported in a large vari-
ety of human cancers including epithelial cancers from
the colon and ovary [29-33].
Altered expression of Eph receptors and their ephrin
ligands has been reported in a large variety of human
cancers including epithelial cancers from the colon and
ovary [29-33]. This was therefore an area that we were
interested to look at to determine whether treatment with
EPA could result in perturbation of these pathways and to
elucidate whether the mechanism by which high fish con-
sumption is associated with a reduced incidence of col-
orectal cancer could be via Eph receptor pathways. The
apparent increase in EphA1 expression seen in the arrays
experiment as a result of EPA treatment was not repli-
cated in the second experiment and so no further analysis
of this gene and protein were undertaken. However,
EphB4 gene expression was significantly higher in EPA
treated cells than in untreated cells by 8 hr after media
change but EphB4 protein expression was significantly
down-regulated at this time point with respect to both
untreated and AA treated HT29 cells. This apparently
contradictory result could be explained by the observa-
tion that at earlier time point's treatment with EPA led to
a down-regulation in EphB4 expression as compared to
untreated cells. Allowing time for this to be translated
into protein production the down-regulation in EphB4
expression by EPA treatment at 8 hr is expected. How-
ever, the AA data do not support such an explanation as
this is even more down-regulated initially but there is no
difference in protein expression. These data suggest that
EphB4 protein is not well correlated with the mRNA lev-
els for this gene and we postulate that there must be a
considerable degree of post-translational control.
Table 4: Fold changes of key genes altered after EPA treatment in the Ephrin receptor network.
Gene of interest Length of treatment (hr) fold expression Adjusted P value
EphB4 8 2.2 0.02
24 1.8 0.02
EphA1 8 2.0 0.02
24 1.6 0.03
Vav2 8 1.1 0.82
24 2.2 0.01
Fold changes of key genes identified as significantly altered after EPA treatment of HT29 cells in the Ephrin receptor network. Analysis of 
microarray data was performed in R as detailed in the materials and methods and includes a Benjamini Hochberg false discovery rate of less 
than 5%. All data are expressed relative to an untreated control.Doleman et al. Nutrition & Metabolism 2010, 7:56
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Figure 1 EPA induced changes in the expression of EphB4, Vav2 
and EphA1. EPA induced changes in the expression of EphB4, Vav2 
and EphA1 in HT29 cells as determined by microarray and real-time RT-
PCR (TaqMan) over a 24 hr time course in two separate experiments. 
Data are expressed as log fold change relative to untreated control 
cells at the same time point. All data is normalized to the initial sample 
taken immediately after changing the media (< 20 min.). Open circles 
denote microarray data and filled triangles denote real-time RT-PCR 
TaqMan data. Each data point depicts the mean of 2-4 flasks of cells. 
The error bars represent standard deviation with significant difference 
relative to untreated cells (p < 0.05) represented by * for TaqMan data 
and ‡ for microarray data. (A) EphB4 is up-regulated in response to EPA 
treatment at 8 and 24 hr by more than 2 fold. B) Vav2 is up-regulated 
in response to EPA treatment as determined by real-time RT-PCR anal-
ysis at 24 hr by both microarray analysis (p < 0.05) and real-time RT-PCR 
(p < 0.02 - relative to expression between 1-6 hr). C) EphA1 is up-regu-
lated at 8 and 24 hr in the first experiment using microarray analysis but 
not in the second experiment using real-time RT-PCR.
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Figure 2 Effects of EPA and AA on EphB4 gene, Vav2 and EphA1 
expression in HT29 cells as determined by real-time RT-PCR anal-
ysis. All data are expressed relative to β-Actin, allowing comparison to 
figure 3. Each data point represents the log of the mean and standard 
deviation of three replicate flasks of cells which were untreated, treat-
ed with EPA or AA over a 24 hr time course. (EPA closed squares, AA 
closed diamonds and untreated open circles). Significantly different 
values are represented by * (comparing EPA to untreated); ** (compar-
ing EPA to AA). ‡ (comparing AA to both untreated and EPA). A) EphB4 
expression is significantly affected by time (p < 0.02) and treatment p 
< 0.001). Post-hoc tests show significant treatment effect for AA (p < 
0.001) and not EPA (p = 0.06). Individual time point analysis showed 
EPA significantly up-regulated EphB4 at 8 hr relative to AA (p = 0.05) 
and untreated (p = 0.09) and at 24 hr expression was still elevated but 
not significantly. B) Vav2 expression is significantly affected by time (p 
< 0.001) and treatment (p = 0.003) and the effect was associated with 
AA (p = 0.002). AA treatment reduced expression levels at 2 hr as com-
pared to EPA (p = 0.005) and untreated (p = 0.05) but EPA treatment 
was non-significant compared to untreated cells (p = 0.1). At 24 hr 
Vav2 expression was higher in EPA treated than untreated cells but not 
significantly (p = 0.4). C) EphA1 expression is significantly affected by 
time (p = 0.01) and treatment (p < 0.001). At 4 hr there is a significant 
increase in gene expression (p = 0.006) and again at 24 hr (p = 0.01). 
This is associated with decreased expression of EphA1 in response to 
AA compared to EPA (p = 0.002) and untreated cells (p < 0.001) over 
the time course, however at individual time points no significant effect 
was detected.
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In the intestinal epithelium EphB receptors are Wnt
signaling target genes that control cell compartmentaliza-
tion along the crypt axis [34]. EphB4 expression in nor-
mal healthy colon is low and outlines the membranes of
intestinal 'precursors' at the base of the crypt. It has also
been found to be consistently over-expressed in tumor
cells of early adenomas when compared to normal tissue
[30,35], with expression shown to be high (50-100% posi-
tive cells) in dysplastic aberrant crypt foci and small ade-
nomas. This high level of expression is shown to be lost
during colorectal cancer progression at the adenoma-car-
cinoma transition and was absent in advanced colorectal
tumors [36]. This down-regulation during cancer pro-
gression was also observed for EphB2. This would suggest
a role for EphBs as a tumor suppressor. The causal role of
EphB silencing in colorectal cancer progression is sup-
ported by the observation that a reduction in EphB activ-
ity exacerbates colorectal tumorigenesis in ApcMin/+ mice
[36]. It has also been reported that EphB2 has a role in the
maintenance of normal tissue architecture in the prostate
and mutational inactivation is present in a significant
fraction of prostate tumors, suggesting a role for EphB2
in the progression and metastasis of prostate cancer [37].
Thus it is feasible that EPA might suppress carcinogenesis
by preventing the down-regulation of EphB activity,
although this may well not be directly as a consequence of
modified gene expression. The different expression levels
of the EphBs in tumor progression and our observed
inconsistency between gene and protein expression,
highlight the complexity of the pathways involved. Ini-
tially increased expression and activation of the pathways
appear to benefit tumor growth but ultimately this
increased expression imposes restrictions on subsequent
tumor progression [36]. Interestingly, it has recently been
reported that tumor cells expressing EphB receptors were
restricted to large homogeneous clusters by the ligands
ephrin-B1 and ephrin-B2 [38]. This response was stron-
gest for ephrin-B1 +EphB2 and ephrin-B1 + EphB3 with
the response from ephrin-B1 and EphB4 only producing
minor modifications in cell distribution and compart-
mentalization in the DLD1 colorectal adenocarcinoma
and Co115 colon carcinoma cells lines used in that study.
This cell compartmentalization subsequently led to a
suppression of tumor progression beyond the earliest
stage. HT29 cells have very low levels of EphB3 and
EphB2 [36], whether the increase in EphB4 protein
expression after exposure to EPA was sufficient to induce
the compartmentalization response would require fur-
ther work However this could suggest a mechanism by
which the increase in EphB4 protein expression after
e x p o s u r e  t o  E P A  i n  H T 2 9  c e l l s  m i g h t  b e  b e n e f i c i a l  i n
terms of halting cancer progression from adenoma
through to invasive carcinoma.
The routes by which PUFAs might mediate EphB4
expression remain a matter of conjecture. Transcriptional
regulation analysis in MetaCore gave no clear evidence of
any one particular transcription factor being involved in
the control of gene expression by the tested PUFAs in this
study (data not included), but it is recognized that EphB4
expression is regulated by one of the HOX family of pro-
teins (HOXA9) and in turn these have been shown to be
involved in signaling by other lipophilic molecules,
namely steroids and retinoic acid [39].
Vav2 protein expression increased over the 24 hr post
media change for all treatments while gene expression
initially dropped relative to the initial time point. This
suggests that Vav2 expression is sensitive to the stress
associated with media change. Protein expression was
Figure 3 EPA treatment of HT29 cells leads to significant changes 
of EphB4 and Vav2 protein expression. EPA treatment of HT29 cells 
leads to significant changes of EphB4 and Vav2 protein expression lev-
els as determined by western blotting. Densitometry measurements 
were taken on a Bio-Rad multi-imager and all data is expressed relative 
to the house-keeper protein, β-actin, allowing direct comparison of 
protein expression data to gene expression data as shown in figure 2. 
EPA treated cells are represented by black bars, AA treated cells by grey 
bars and untreated cells by white bars. Data are presented as the mean 
and SD of n = 3 (n = 2 at 4 hr). A) EphB4 protein was not detectable until 
8 hr after media change. At 8 hr EPA treatment led to lower protein lev-
els compared to both untreated and AA treated HT29 cells (p = 0.007 
and p = 0.034 respectively). There was a highly significant increase in 
protein levels between 8 hr and 24 hr in all treatment groups (p < 
0.005). B) Vav2 protein expression was significantly up-regulated after 
4 hr irrespective of treatment (p < 0.05). At 8 hr levels of Vav2 protein 
were significantly elevated by EPA treatment as compared to untreat-
ed control cells (p = 0.043).
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also higher at 8 hr in EPA treated cells but again these
changes were not reflected at the gene transcript level.
Vav2 is the second member of the Vav oncogene family
a n d  u n l i k e  V a v 1 ,  w h i c h  i s  r e s t r i c t e d  t o  h e m a t o p o i e t i c
cells, Vav2 has been found to be expressed ubiquitously
[40]. It is a Rho family guanine nucleotide exchange fac-
tor and Vav2 has been shown to have a role in growth fac-
tor signaling to the cytoskeleton [41] and is required for
integrin-dependant activation of Rac during cell spread-
ing [42]. It has recently come to light that in breast cancer
tissue the levels of Vav2 expression as compared to nor-
mal or hyperplasic epithelium are down-regulated [43].
Vav2 acts downstream of the Eph A and B receptors in
the receptor pathway and its perturbation in breast can-
cer progression is very relevant to the work we undertook
in HT29 cells. Vav2 is important in mediating cytotoxic
lymphocyte activity [44] against target cells including
cancer cells, but studies in epithelial cells using siRNA
knock-down of Vav2 suggest an important role in stimu-
lating cell migration [45]. It may therefore be that one of
the mechanisms by which a diet high in n-3 PUFAs may
inhibit the development of colorectal cancer is by pre-
venting the down-regulation of Vav2 levels and thereby
limiting cancer progression.
In general we saw little difference in response to EPA
and AA over the first 6 h after changing the media,
although the response to AA was if anything stronger
than to EPA for both EphB4 and Vav2. These changes
closely follow the changes in redox status mentioned pre-
viously and so may be a response to a transitory increase
in oxidative stress. However, this association is by no
means conclusive and the observed effects could equally
well be associated with similar affinities for some nuclear
receptors, for example RXR [46]. Alternatively the early
transitory responses may reflect the disappearance of
EPA from the medium. Peak intracellular concentrations
of EPA are found at 6 h [25], and thus it may be that we
see an initial short-term exposure effect, followed by a
more subtle response to the smaller but more sustained
differences in PUFA content found after 8-14 hr. At these
later times, responses to EPA and AA were dissimilar,
such that the expression of both the EphB4 and Vav2
genes was generally higher in those cells exposed to EPA
n-3 PUFA than in those exposed to AA n-6 PUFA.
Conclusions
Although these studies have been conducted in a tumor
cell line, the observation that EPA can change expression
of EphB4 may have wider implications and should be
investigated further in a wider range of biological sys-
tems. For example, the recognized role of Eph receptor
signaling in neuronal development [47] may provide at
least a partial explanation for the suggested benefits of
these PUFAs in relation to cognitive function [48,49]. The
health benefits associated with the consumption of very
long chain PUFAs of the n-3 series are as yet poorly
understood at the molecular level. This study suggests a
novel mechanism by which these fatty acids may mediate
a wide range of health benefits including limiting cancer
progression through modulation of the Eph receptor
pathways.
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